Latest Conference Articles

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.

The growing role of biomarker-driven treatment selection in breast cancer and how pharmacists can help optimize therapy sequencing, toxicity management, and personalized care.

Key distinctions among bispecific therapies, toxicity management considerations, and the pharmacist’s role in safely implementing these agents across academic and community oncology settings.

McKesson ideaShare 2026 brings independent pharmacy's premier gathering to Denver, June 18-21, with Pharmacy Times on-site for exclusive interviews and coverage.

Minimal residual disease (MRD) negativity exceeded 90% with 100% response and no progression in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This is an encore presentation from the 2025 American Pharmacists Association Annual Meeting and Exposition in Nashville, Tennessee. This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Data showed that talquetamab combined with daratumumab, with or without pomalidomide, significantly improved PFS, OS, response rates, and MRD negativity.

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

European Hematology Association 2026 data show sonrotoclax plus zanubrutinib drives rapid, durable undetectable minimal residual disease in frontline chronic lymphocytic leukemia, even in patients with TP53 mutations and 17p deletions.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

Data presented at the 2026 European Hematology Association Congress continue to support venetoclax plus obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia.

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Jessica Dunne, PhD, discusses why adult type 1 diabetes (T1D) is frequently misdiagnosed as T2D in patients with gestational diabetes mellitus (GDM) and how autoantibody testing could close the diagnostic gap.

Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, highlights key data and events at the 2026 NLA Scientific Sessions.

High-dose oral semaglutide pills boost A1C control and double-digit weight loss in diabetes and obesity trials, offering injectable-level results with daily convenience.

Jessica Dunne, PhD, discusses why adult T1D is frequently misdiagnosed as T2D and how autoantibody testing could close the diagnostic gap.

A post hoc analysis of the AT HOME-HF trial found lower hospitalization rates and longer time to admission among patients with diabetes treated with subcutaneous furosemide compared with usual care.

A poster presented at the 2026 ADA Scientific Sessions underscores the importance of individualized dose titration for patients with type 1 diabetes (T1D) utilizing Technosphere inhaled insulin.

New SYNCHRONIZE data signal broad metabolic and hepatic benefits.

A pilot survey presented at ADA Scientific Sessions found that although health care professionals reported high awareness of DSMES, important gaps in actual understanding remain.

Dave Dixon, PharmD, examines why SGLT2 inhibitor and GLP-1 uptake remain low and how pharmacists can bridge the gap between evidence and implementation.

Expert Lance Sloan, MD, MSE, FACE, FASN, FACP, FEAA, FASPC, discusses CATALYST trial data on mifepristone, glucagon-like peptide-1 receptor agonist (GLP-1 RA) resistance, and screening for hypercortisolism in uncontrolled type 2 diabetes (T2D).